Enumeral Biomedical Holdings Inc

Enumeral Biomedical — Investor Presentation (April 2015)

23 slides from Enumeral Biomedical's investor presentation, Apr 7, 2015

  1. Slide 1: Enumeral Biomedical Antibody Immunotherapy Programs

    Enumeral Biomedical Antibody Immunotherapy Programs April 2015

  2. Slide 2: Enumeral Overview

    Enumeral Overview Enumeral’s mission is to discover and develop best - in - class antibody immunotherapies using our proprietary platform that uniquely leverages human cell biology • The field agrees that combination therapies will be necessary to drive higher response rates… • … And that there is c

  3. Slide 3: Executive Summary

    Executive Summary • Enumeral Program Overview – Sequence diversity, binding data, and initial functional data provided for PD1 program. – Enumeral anti - PD1 candidates show comparable binding characteristics and superior EC 50 data vs Keytruda and superior ability to disrupt functional inhibition f

  4. Slide 4: Enumeral Immunotherapy Programs: Anti-PD1 mAbs & Pipeline Update

    Enumeral Immunotherapy Programs Anti - PD1 mAbs & Pipeline Update

  5. Slide 5: Enumeral Discovery Advantages

    Enumeral Discovery Advantages • Discovery from primary cells, from any tissue and species leverages the mammalian immune system to its full potential Samples the full breadth of clonal diversity – Combinatorial in vitro methods like phage display lose all advantages of somatic hypermutation and affi

  6. Slide 6: Anti-PD-1 mAbs – Opportunity

    Anti - PD - 1 mAbs – Opportunity 6 Figure Credit: http ://www.hematology.org/The hematologist/Diffusion/2560.aspx • Opportunity : anti - PD1 mAbs developed with advanced understanding of functional immune profile opens doors to new tumor types, combinations , and applications outside of oncology • C

  7. Slide 7: Anti-PD1 Program: Maximizing Functional Heterogeneity of Antibody Library

    Anti - PD1 Program: Maximizing Functional Heterogeneity of Antibody Library • Screening program aimed at high sequence diversity – Multiple strains: Black6 , BalbC – Confirmed class switching prior to screening – Screen primary splenocytes , not hybridoma • Proprietary platform prioritizes hits – Sc

  8. Slide 8: Anti-PD1 Program Sequence Diversity

    Anti - PD1 Program Sequence Diversity 8 1 2 3 • Enumeral proprietary libraries • ~10 months - generation of broad sequence diversity • Unprecedented functional diversity compared to other approaches • Boxes indicate competitors’ IP: – 1 - BMY, 2 - MRK, 3 - MDVN • Potential for strong intellectual pr

  9. Slide 9: Enumeral mAb candidate Binding to cell-surface expressed PD-1

    Enumeral mAb candidate Binding to cell - surface expressed PD - 1 (HEK293) 100244_C7VH10_C8VK5 ++ 100244_C7VH10_C8VK5m1 ++ 100244_C8VH3_C8VK5 ++ 100244_C8VH3_C8VK5m1 ++ 100246_F7VH3_F7VK2 ++ 100258_C1VH4_C1VK1 + 100258_F6VH4_F6VK1 ++ 100258_F6VH4_F6VKm1 ++ 100392_C4VH5_C4VK8 +++ 100394_D5VH9_D5VK7 +

  10. Slide 10: Binding Affinity: ENUM mAbs vs. Keytruda

    Binding Affinity: ENUM mAbs vs. Keytruda mAb EC 50 Keytruda 0.066 ENUM - A10 0.020 ENUM - C8 0.005 ENUM - D4 0.003 ENUM - E1 0.013 ENUM - D2 0.005 10 0 0.5 1 1.5 2 2.5 3 3.5 OD (450nm) Antibody concentration ( μ g/mL) Several ENUM mAbs show superior EC 50 vs Keytruda

  11. Slide 11: Binding to Non-human Primate PD-1

    Binding to Non - human Primate PD - 1 11 Antibody Concentration ( m g/ml) OD (450nm) 0 0.5 1 1.5 2 2.5 3 3.5 388D4 413E1 413D2 PD1 biolegend • Assay for binding to cynomolgous PD1 • All ENUM lead clones bind to non - human primate (NHP) PD1 • Confirmatory testing for binding to cellular NHP PD1 in p

  12. Slide 12: Platform-based Functional Assays

    Platform - based Functional Assays 12 Proprietary functional immune signatures Biopsy Tissues Enumeral Platform Elite Responders Non - Responders • Immune regulatory molecules can be expressed on many cell types • Target validation for multiple checkpoint programs Rational selection of combination s

  13. Slide 13: Platform-based Functional Assays

    Platform - based Functional Assays • Ideal method to identify candidate mAbs with the desired functional profile within a given indication – antagonists vs agonists • PD1 example: Measure stimulated cells in presence of PDL1 – does mAb allow activation of lymphocytes & restore function? (Next slide)

  14. Slide 14: PDL1 Suppression Assay

    PDL1 Suppression Assay 14 IFNg secretion (relative to control) N = 5 repetitions for each candidate/condition • PBMC - based assay to determine mAb’s ability to disrupt functional suppression from PDL1 • ENUM candidates compared with : – Control ( stim /no PDL1) – PDL1 (suppress resp.) – Keytruda •

  15. Slide 15: Pipeline Update

    Pipeline Update Program Screening Initiated Hit Selection Status PD1 Q2 2014 349 Vh amino acid sequences , 28 families Analysis of ex - vivo function via PICTURE; Affinity, epitope mapping, humanization TIM3 Q1 2015 200 + hits in - process Lead - selection from n=11 antibody clones LAG3 Q1 2015 30+

  16. Slide 16: PD1 & Combinations Beyond Cancer

    PD1 & Combinations Beyond Cancer • Can PD - 1 be a target outside of oncology? – Applicability of PD1 axis being explored in multiple indications – Importance of T - cell – or other immune cells expressing PD1 – in disease progression or effective response • Therapeutic approach: Antagonism, depleti

  17. Slide 17: Target Validation in Human Tissues and Rational Selection of Combination Therapies

    Target Validation in Human Tissues and Rational Selection of Combination Therapies

  18. Slide 18: Enumeral Pipeline Positioned for Combinatorial Immunotherapy

    Enumeral Pipeline Positioned for Combinatorial Immunotherapy 18 Lesokhin et al STM 2015 Target validation and functional deconvolution, all performed on human tissues, gives Enumeral an advantage in “breaking the code” surrounding effective and safe combinations in immuno - oncology

  19. Slide 19: Target Validation in Human Tissues

    Target Validation in Human Tissues • Profiling human tissues provides physiologic target validation at putative site of action Solves key problem with common discovery practices • Enumeral targets are validated in human tissues – reduces “translational risk” from murine models to clinical trials • D

  20. Slide 20: Target Validation – PD1 and TIM3

    Target Validation – PD1 and TIM3 • Functional cellular profiles differ between tissue compartments; IFN g secretion from immune cells in mucosal tissue & PBMC shown below • Enumeral validation extends to multiple checkpoint markers in tissue – necessary for rational combination strategy 20

  21. Slide 21: Next Wave of Targets: TIM family

    Next Wave of Targets: TIM family 21 Baghdadi and Jinushi 2014 • TIM - 3 biology originally centered around “exhausted” T cells – Upregulated as negative feedback regulator of activation – Dampen immune response • Emerging data suggests TIM - 3 is expressed on multiple cell types in the tumor microen

  22. Slide 22: Enumeral Clinical Impact

    Enumeral Clinical Impact • Does the selective activation of certain immune cells result in better efficacy? – Does this correlate with response rate or durability? • How do we know elevated IFN g or granzyme B is only from effector cells? (And what cells are they…. T cells? NK cells?) • Can we funct

  23. Slide 23: The Power of Human – Contact

    THE POWER of HUMAN™ Contact: Derek Brand Vice President of Business Development 917 - 225 - 8669 Derek@Enumeral.com

Enumeral Biomedical Holdings — Investor Presentation (April 2015) on 6ix